- Home
- BCDA vs AMBO Comparison
BCDA vs AMBO Comparison
Compare BCDA & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- AMBO
- Stock Information
- Founded
- BCDA N/A
- AMBO 2000
- Country
- BCDA United States
- AMBO United States
- Employees
- BCDA N/A
- AMBO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- AMBO Other Consumer Services
- Sector
- BCDA Health Care
- AMBO Real Estate
- Exchange
- BCDA Nasdaq
- AMBO Nasdaq
- Market Cap
- BCDA 10.1M
- AMBO 7.0M
- IPO Year
- BCDA N/A
- AMBO 2010
- Fundamental
- Price
- BCDA $2.33
- AMBO $2.71
- Analyst Decision
- BCDA Strong Buy
- AMBO
- Analyst Count
- BCDA 1
- AMBO 0
- Target Price
- BCDA $25.00
- AMBO N/A
- AVG Volume (30 Days)
- BCDA 239.0K
- AMBO 11.7K
- Earning Date
- BCDA 08-12-2025
- AMBO 01-01-0001
- Dividend Yield
- BCDA N/A
- AMBO N/A
- EPS Growth
- BCDA N/A
- AMBO N/A
- EPS
- BCDA N/A
- AMBO 0.11
- Revenue
- BCDA $3,000.00
- AMBO $9,392,000.00
- Revenue This Year
- BCDA N/A
- AMBO N/A
- Revenue Next Year
- BCDA N/A
- AMBO N/A
- P/E Ratio
- BCDA N/A
- AMBO $27.31
- Revenue Growth
- BCDA N/A
- AMBO 2.50
- 52 Week Low
- BCDA $1.63
- AMBO $1.00
- 52 Week High
- BCDA $4.66
- AMBO $5.55
- Technical
- Relative Strength Index (RSI)
- BCDA 58.67
- AMBO 60.08
- Support Level
- BCDA $1.98
- AMBO $2.25
- Resistance Level
- BCDA $2.45
- AMBO $2.70
- Average True Range (ATR)
- BCDA 0.17
- AMBO 0.29
- MACD
- BCDA 0.04
- AMBO 0.08
- Stochastic Oscillator
- BCDA 88.00
- AMBO 72.97
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.